Menu
Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent, its first MIGS device, in the United States in 2012, its next-generation iStent inject device in the United States in 2018, and most recently, the iStent inject W device in 2020. In corneal health, Glaukos' proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.
229 Avenida Fabricante
San Clemente, California 92672-7531
Phone: 19493679600
www.glaukos.com
The share price of Glaukos Corporation (NYSE:GKOS) rose to $48.51 per share on Wednesday from $47.23. While Glaukos Corporation has overperformed by 2.71%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, GKOS fell by -12.29%, with highs and lows ranging from $64.49 to $33.33, whereas the […]
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iDose TR. iDose TR is a micro-invasive intraocular implant designed to continuously deliver
https://www.investing.com/news/pro/glaukos-corporation-pt-lowered-to-55-at-piper-sandler-432SI-3011825
https://www.investing.com/news/pro/glaukos-corporation-pt-raised-to-59-at-citi-432SI-3011605
Glaukos Corporation (NYSE:NYSE:GKOS) Q4 2022 Earnings Conference Call February 22, 2023 4:30 PM ETCompany ParticipantsChris Lewis – Vice President-Investor Relations and Corporate…
ALISO VIEJO, Calif. (AP) — ALISO VIEJO, Calif. (AP) — Glaukos Corp. (GKOS) on Wednesday reported a loss of $31.5…
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2022. Key highlights include: Net sales of $71.2 million in Q4 2022. Glaucoma net sales of $52.9 million and Corneal Health net sales of $18.3 million in Q4 2022. Gross margin of
Glaukos (NYSE: GKOS ) is set to give its latest quarterly earnings report on Wednesday, 2023-02-22. Here''s what investors need to know before the announcement. Analysts estimate that Glaukos will report an earnings per share (EPS) of $-0.55. Glaukos bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next … Full story available on Benzinga.com
Glaukos Corp. continues to exhibit positive clinical trial momentum, yet hasn''t been rewarded by investors on this. See why we rate GKOS stock a Hold.
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2022 financial results after the market close on Wednesday, February 22, 2023. The company’s management will discuss the results during a conference call and